NxStage Medical (NSDQ:NXTM) named Robert Funari to replace Philippe Chambon as non-executive chairman after 15 years on the medical device company’s board of directors.
Cooley LLP
Devices plus drugs may mean an earlier payoff
Companies combining valuable devices with known drugs may be able to land a high-value exit before ever hitting the market, MIT researcher Michael Cima told a group of medical device industry leaders today.
Speaking at the Cooley Medical Device Growth conference in Boston, Cima urged med-tech companies and investors to consider drug-device combinations, acknowledging a higher up-front risk with the potential for an earlier and larger reward.